Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 5,263 · FY2023 3,189 · FY2024 2,737 — 3-yr total 11,189
Georgian pharmaceutical importer and wholesale distributor. Limited public information available beyond the Reportal filing.
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 4,860 | 7,760 | 2,978 | 12,616 | 8,880 | 11,321 | 6,493 | 12,244 | +14.1% |
| Net Cash used in Investing Activities | 0 | 518 | 4,763 | 4,339 | 6,342 | 6,306 | 7,382 | 3,529 | +37.7% |
| Free Cash Flow (OCF − Capex proxy) | 4,860 | 7,242 | 1,786 | 8,277 | 2,538 | 5,015 | 888 | 8,715 | +8.7% |
| Net Cash from Financing Activities | 0 | 752 | 955 | 3,145 | 2,747 | 6,306 | 4,351 | 12,824 | nmf |
| Net Change in Cash (before FX) | 4,860 | 7,994 | 830 | 5,132 | 5,285 | 1,292 | 5,239 | 4,109 | nmf |
| Effect of FX on Cash | 0 | 63 | 22 | 388 | 830 | 51 | 50 | 95 | +7.2% |
| Net Change in Cash (incl. FX) | 4,860 | 7,931 | 852 | 5,520 | 4,455 | 1,342 | 5,289 | 4,204 | nmf |
| Cash at Beginning of Year | 0 | 3,861 | 11,792 | 4,308 | 9,828 | 14,283 | 12,941 | 7,652 | +12.1% |
| Cash at End of Year | 0 | 11,792 | 10,940 | 9,828 | 14,283 | 12,941 | 7,652 | 3,447 | -18.5% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →